• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

年龄大于 70 岁和 Charlson 合并症指数大于 3 与膀胱癌根治性膀胱切除术后生存概率降低相关。来自 334 例连续患者的当代系列数据。

Age above 70 years and Charlson Comorbidity Index higher than 3 are associated with reduced survival probabilities after radical cystectomy for bladder cancer. Data from a contemporary series of 334 consecutive patients.

机构信息

Department of Urology, Ospedale Nuovo Legnano, Ospedale Fornaroli Magenta, Milano.

Clinical Epidemiology Unit, IRCCS Policlinico San Martino, University of Genova.

出版信息

Arch Ital Urol Androl. 2021 Mar 18;93(1):15-20. doi: 10.4081/aiua.2021.1.15.

DOI:10.4081/aiua.2021.1.15
PMID:33754602
Abstract

OBJECTIVE

To assess the joint effect of age and comorbidities on clinical outcomes of radical cystectomy (RC).

METHODS

334 consecutive patients undergoing open RC for bladder cancer (BC) during the years 2005-2015 were analyzed. Pre-, peri- and post-operative parameters, including age at RC (ARC) and Charlson Comorbidity Index (CCI), were evaluated. Overall and cancer-specific survivals (OS, CSS) were assessed by univariate and multivariate modelling. Furthermore, a three-knot restricted cubic spline (RCS) was fitted to survival data to detect dependency between death-rate ratio (HR) and ARC.

RESULTS

Median follow-up time was 3.8 years (IQR = 1.3-7.5) while median OS was 5.9 years (95%CL = 3.8-9.1). Globally, 180 patients died in our cohort (53.8%), 112 of which (62.2%) from BC and 68 patients (37.8%) for unrelated causes. After adjusting for preoperative, pathological and perioperative parameters, patients with CCI > 3 showed significantly higher death rates (HR = 1.61; p = 0.022). The highest death rate was recorded in ARC = 71-76 years (HR = 2.25; p = 0.034). After fitting an RCS to both OS and CSS rates, two overlapping nonlinear trends, with common highest risk values included in ARC = 70-75 years, were observed.

CONCLUSIONS

Age over 70 years and CCI > 3 were significant factors limiting the survival of RC and should both be considered when comparing current RC outcomes.

摘要

目的

评估年龄和合并症对根治性膀胱切除术(RC)临床结果的联合影响。

方法

分析了 2005 年至 2015 年间接受开放 RC 治疗膀胱癌(BC)的 334 例连续患者。评估了术前、术中和术后参数,包括 RC 时的年龄(ARC)和 Charlson 合并症指数(CCI)。通过单变量和多变量建模评估总生存率(OS)和癌症特异性生存率(CSS)。此外,还对生存数据进行了三结限制立方样条(RCS)拟合,以检测死亡率比(HR)与 ARC 之间的依赖性。

结果

中位随访时间为 3.8 年(IQR = 1.3-7.5),中位 OS 为 5.9 年(95%CL = 3.8-9.1)。在我们的队列中,共有 180 名患者死亡(53.8%),其中 112 名(62.2%)死于 BC,68 名(37.8%)死于无关原因。在调整了术前、病理和围手术期参数后,CCI>3 的患者死亡率显著更高(HR = 1.61;p = 0.022)。ARC = 71-76 岁的患者死亡率最高(HR = 2.25;p = 0.034)。对 OS 和 CSS 率进行 RCS 拟合后,观察到两个重叠的非线性趋势,ARC = 70-75 岁时包含了共同的最高风险值。

结论

年龄超过 70 岁和 CCI>3 是限制 RC 生存的重要因素,在比较当前 RC 结果时应同时考虑这两个因素。

相似文献

1
Age above 70 years and Charlson Comorbidity Index higher than 3 are associated with reduced survival probabilities after radical cystectomy for bladder cancer. Data from a contemporary series of 334 consecutive patients.年龄大于 70 岁和 Charlson 合并症指数大于 3 与膀胱癌根治性膀胱切除术后生存概率降低相关。来自 334 例连续患者的当代系列数据。
Arch Ital Urol Androl. 2021 Mar 18;93(1):15-20. doi: 10.4081/aiua.2021.1.15.
2
The Charlson comorbidity index predicts survival after disease recurrence in patients following radical cystectomy for urothelial carcinoma of the bladder.查尔森合并症指数可预测膀胱尿路上皮癌患者根治性膀胱切除术后疾病复发后的生存率。
Urol Int. 2014;93(3):303-10. doi: 10.1159/000362421. Epub 2014 Aug 19.
3
The SPARC score: a multifactorial outcome prediction model for patients undergoing radical cystectomy for bladder cancer.SPARC 评分:用于膀胱癌根治性切除术患者的多因素预后预测模型。
J Urol. 2013 Dec;190(6):2005-10. doi: 10.1016/j.juro.2013.06.022. Epub 2013 Jun 14.
4
Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection.在经尿道膀胱肿瘤切除术再分期时,对于残余 T1 膀胱癌患者,即刻根治性膀胱切除术的作用。
BJU Int. 2013 Jul;112(1):54-9. doi: 10.1111/j.1464-410X.2012.11391.x. Epub 2012 Nov 13.
5
Impact of Routine Laboratory Parameters in Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: A Long-Term Follow-Up.根治性膀胱切除术治疗尿路上皮膀胱癌患者常规实验室参数的影响:长期随访。
Urol Int. 2020;104(7-8):551-558. doi: 10.1159/000506263. Epub 2020 Feb 28.
6
Fluorescence-guided bladder tumour resection: impact on survival after radical cystectomy.荧光引导下膀胱肿瘤切除术:对根治性膀胱切除术后生存率的影响。
World J Urol. 2015 Oct;33(10):1429-37. doi: 10.1007/s00345-015-1485-8. Epub 2015 Jan 17.
7
Comparative performance of comorbidity indices for estimating perioperative and 5-year all cause mortality following radical cystectomy for bladder cancer.比较几种合并症指数在预测膀胱癌根治性切除术围手术期和 5 年全因死亡率方面的性能。
J Urol. 2013 Jul;190(1):55-60. doi: 10.1016/j.juro.2013.01.010. Epub 2013 Jan 9.
8
Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality.接受根治性膀胱切除术的膀胱癌患者的肌肉减少症:对癌症特异性死亡率和全因死亡率的影响。
Cancer. 2014 Sep 15;120(18):2910-8. doi: 10.1002/cncr.28798. Epub 2014 May 19.
9
Preoperative chronic kidney disease is predictive of oncological outcome of radical cystectomy for bladder cancer.术前慢性肾脏病可预测膀胱癌根治性切除术的肿瘤学结局。
World J Urol. 2018 Feb;36(2):249-256. doi: 10.1007/s00345-017-2141-2. Epub 2017 Nov 28.
10
Peri-operative allogeneic blood transfusion and outcomes after radical cystectomy: a population-based study.根治性膀胱切除术围手术期异体输血与结局:一项基于人群的研究。
World J Urol. 2017 Sep;35(9):1435-1442. doi: 10.1007/s00345-017-2009-5. Epub 2017 Feb 17.

引用本文的文献

1
Artificial intelligence for rare bladder cancer variants: a new hope for detection?用于罕见膀胱癌变体的人工智能:检测的新希望?
Int Urol Nephrol. 2025 Jul 4. doi: 10.1007/s11255-025-04647-3.
2
Open radical cystectomy and ileal loop diversion under combined spinal-epidural anaesthesia for the elderly and frail.在老年体弱患者中采用腰麻-硬膜外联合麻醉行开放性根治性膀胱切除术及回肠膀胱术。
BMC Surg. 2025 May 22;25(1):222. doi: 10.1186/s12893-025-02947-0.
3
Comment on: "A review and meta-analysis: comparing the efficacy of robot-assisted and open radical cystectomy in elderly bladder cancer patients".
评论:“一项综述与荟萃分析:比较机器人辅助根治性膀胱切除术与开放性根治性膀胱切除术在老年膀胱癌患者中的疗效”
J Robot Surg. 2025 May 6;19(1):199. doi: 10.1007/s11701-025-02376-4.
4
A review and meta-analysis: comparing the efficacy of robot-assisted and open radical cystectomy in elderly bladder cancer patients.一项综述与荟萃分析:比较机器人辅助根治性膀胱切除术与开放性根治性膀胱切除术在老年膀胱癌患者中的疗效
J Robot Surg. 2025 Apr 22;19(1):168. doi: 10.1007/s11701-025-02323-3.
5
The Characterization of Non-oncologic Chronic Drug Therapy in Bladder Cancer Patients and the Impact on Recurrence-Free and Cancer-Specific Survival: A Prospective Study.膀胱癌患者非肿瘤慢性药物治疗的特征及其对无复发生存率和癌症特异性生存率的影响:一项前瞻性研究。
J Clin Med. 2023 Oct 25;12(21):6749. doi: 10.3390/jcm12216749.
6
Identification of age- and immune-related gene signatures for clinical outcome prediction in lung adenocarcinoma.鉴定肺腺癌临床结局预测的年龄和免疫相关基因特征。
Cancer Med. 2023 Aug;12(16):17475-17490. doi: 10.1002/cam4.6330. Epub 2023 Jul 11.
7
Postoperative clinical outcomes of patients with thymic epithelial tumors after over-3-year follow-up at a single-center.单中心 3 年以上随访的胸腺瘤患者的术后临床结局。
J Cardiothorac Surg. 2023 Feb 21;18(1):77. doi: 10.1186/s13019-023-02169-6.
8
Survival outcomes of non-definitive therapy for muscle-invasive bladder cancer.肌肉浸润性膀胱癌非确定性治疗的生存结果。
Oncol Lett. 2022 Apr;23(4):126. doi: 10.3892/ol.2022.13246. Epub 2022 Feb 17.